VERU INC.
VERUDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
VERU Earnings Report
EPS Est: $-0.34 | FQ end 2026-06
How VERU's past catalysts played out
Veru-111
Respiratory Distress Syndrome, Adult
Veru-944
Prostate Cancer Metastatic
Enobosarm
Muscle Loss
Semaglutide (Wegovy) weekly injection
Obesity & Overweight
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Veru-111 | Phase 3 | Respiratory Distress Syndrome, Adult | - | - |
Veru-944 | Phase 2 | Prostate Cancer Metastatic | - | - |
Enobosarm | Phase 2 | Muscle Loss | - | - |
Semaglutide (Wegovy) weekly injection | Phase 2 | Obesity & Overweight | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in VERU INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in VERU INC.'s (VERU) pipeline across Phase 3, Phase 2. Its lead program is Veru-111 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VERU INC.'s next FDA catalyst?→
VERU INC.'s (VERU) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VERU biotech catalysts?→
Add VERU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VERU INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.